Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 12 posts of 132 posts found.

Novartis drops late stage lung cancer candidate

November 11, 2010
Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …

News

Pfizer to seek US approval for crizotinib next year

November 1, 2010
Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

News

Lung cancer vaccine poised to begin phase IIb/III trials

September 1, 2010
Research and Development NSCLC, TG4010, Transgene, cancer vaccine

French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …

News

Sutent disappoints in lung cancer

August 24, 2010
Research and Development, Sales and Marketing NSCLC, Pfizer, Sutent, Tarceva

Pfizer’s Sutent has failed to improve overall survival in lung cancer patients when combined with Roche’s Tarceva. Pfizer’s SUN 1087 …

News

Avastin will remain gold standard for lung cancer to 2018

June 20, 2010
Decision Resources, NSCLC, Roche drug tipped to remain key to treatment, avastin

 Industry analysts Decision Resources believes that Roche’s Avastin plus chemotherapy agents will remain as the gold standard for the treatment …

News
Tarceva

NICE rejects Tarceva maintenance treatment

June 17, 2010
Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer

Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …

News

Nexavar fails in lung cancer trial

June 15, 2010
Research and Development Bayer, NSCLC, Nexavar, Onyx

Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …

News

Merck gains rights to cancer treatment

May 10, 2010
Research and Development Ariad Pharmaceuticals, Merck & Co, NSCLC

Merck has acquired an exclusive license for a new cancer drug that’s in trials for a number of different forms …

News

Antisoma cancer drug fails in phase III

March 29, 2010
Research and Development Antisoma, NSCLC, lung cancer

UK biotech Antisoma has suffered a disappointing late-stage failure with a potential lung cancer treatment it was developing with Novartis. …

News

Novelos abandons candidate in lung cancer

March 20, 2010
Research and Development NSCLC, breast cancer

 

News

Alimta recommended as maintenance therapy

March 1, 2010
Sales and Marketing Alimta, Cancer, NSCLC, lilly

 NICE has recommended Alimta as a maintenance treatment for people with locally advanced or metastatic non-small cell lung cancer. Patients …

News

Latest news from Datamonitor

June 22, 2007
Research and Development, Sales and Marketing NSCLC, Novartis, Pfizer

 Novartis receives FDA approval for blood pressure medicineNovartis has been granted final FDA approval for Exforge, its high blood pressure …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024